Taking it up a Notch: Nohla sets sights on universal cell therapy
By Jennifer Boggs
Wednesday, April 13, 2016
Nohla Therapeutics Inc., a 2015 spin-off of the Fred Hutchinson Cancer Research Center, has a simply stated yet ambitious goal to create a “truly universal, off-the-shelf” ex vivo-expanded umbilical cord blood stem cell product.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.